Compare Summit Therapeutics Inc (SMMT) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.33. Which is the better fit depends on your goals.
| SMMT | YMAG | |
|---|---|---|
Market Cap | $12.06B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $26.98 | $15.98 |
52-Week Low | $12.55 | $10.76 |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
YMAG trades at $11.29, down 2.59% today, with technical indicators showing a bullish overall signal despite mixed oscillators. The ETF maintains consistent weekly dividend distributions, with recent payouts ranging from $0.07 to $0.40 per share. Recent news highlights YieldMax's distribution announcements and analysis of the fund's option income strategy performance.
The fund's structured option strategy provides high income potential but faces NAV stability challenges during earnings volatility. Key risks include concentrated exposure to Magnificent Seven stocks and option strategy complexity. Technical support sits at $11-12 levels while the bullish moving average trend suggests potential upside momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
